Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
China
Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Harbin Medical University Cancer Hospital, Harbin, Heilongjiang The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan Hubei Cancer Hospital, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi The First Hospital of Jilin University, Changchun, Jilin Liaoning Cancer Hospital & Institute, Shenyang, Liaoning The First Hospital of China Medical University, Shenyang, Liaoning Shanghai Chest Hospital, Shanghai, Shanghai Municipality Yunnan Cancer Hospital, Kunming, Yunnan Zhejiang Cancer Hospital, Hangzhou, Zhejiang